Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UVADEX with Photopheresis for Early Stage CTCL
NCT00221039Phase 4Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Apr 2004
- Primary completion
- Apr 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of methoxsalen in mycosis fungoides (MF), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Overall Response based on skin-weighted assessment at 6 months. Started Apr 2004; status: completed.
02
Drugs
methoxsalen
03
Conditions
mycosis fungoides (MF)
Beyond the preview
Go deeper on NCT00221039.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00221039.